Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

中文翻译：

---

三阴性乳腺癌中通过化疗加检查点阻断的免疫激活和进化

免疫检查点阻断联合化疗正在成为一些三阴性乳腺癌 (TNBC) 患者的标准治疗方法。在本期Cancer Cell 中，Zhang 等人。对治疗前和治疗后 TNBC 进行广泛的单细胞免疫区室分析，它们揭示了 T 细胞活化的潜在机制和免疫进化模式，可能会为未来的反应和临床益处的生物标志物提供信息。